WaveMan
WaveMan · Company
PLSE · Pulse Biosciences, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

PLSE Pulse Biosciences (PLSE) Insider Trading, Ownership & Congress Trades

Medical Devices · Surgical & medical instruments & apparatus · CIK 0001625101
Quote by TradingView
Cluster · 3 insidersC-suite buying · 2
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
68
13F, latest reported quarter

What the filings say about PLSE

Insiders, 180 days
+$13.8M net bought
3 buyers

Pulse Biosciences insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, PULSE BIOSCIENCES, INC. insiders bought a net $13.8M of stock across 68 Form 4 purchases and sales, with 3 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Teplitsky Liane Rae
Chief Operating Officer
BUY
2026-09-02 SECtraded 2026-09-01
1,001
$50.0K
-3.7%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Aug 31, 2026.
  • The trade is 24.4% of the 4,095 shares held after it.
  • No other insider bought within 30 days.
  • 68 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Teplitsky Liane Rae bought about $50.0K of PLSE on Sep 1, 2026; 68 funds added in the latest 13F quarter.
Teplitsky Liane Rae
Chief Operating Officer
BUY
2026-09-02 SECtraded 2026-08-31
1,024
$50.0K
-3.7%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Aug 28, 2026.
  • The trade is 33.1% of the 3,094 shares held after it.
  • No other insider bought within 30 days.
  • 68 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Teplitsky Liane Rae bought about $50.0K of PLSE on Aug 31, 2026; 68 funds added in the latest 13F quarter.
Teplitsky Liane Rae
Chief Operating Officer
BUY
2026-08-28 SEC
1,034
$50.0K
+4.6%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Aug 26, 2026.
  • The trade is 50.0% of the 2,070 shares held after it.
  • No other insider bought within 30 days.
  • 68 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Teplitsky Liane Rae bought about $50.0K of PLSE on Aug 28, 2026; 68 funds added in the latest 13F quarter.
Teplitsky Liane Rae
Chief Operating Officer
BUY
2026-08-28 SECtraded 2026-08-26
1,036
$50.0K
+4.6%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 1,036 shares held after it.
  • No other insider bought within 30 days.
  • 68 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Teplitsky Liane Rae bought about $50.0K of PLSE on Aug 26, 2026; 68 funds added in the latest 13F quarter.
DUGGAN ROBERT W
Director
BUY
2026-05-15 SECtraded 2026-05-11
660,233
$13.0M
+105.6%
Context
  • 23 earlier Form 4 trades (code P or S) here by this insider (23 buys), the last on Sep 10, 2025.
  • +1.8% median (+6.9% mean) 90-day return after 19 previous buys.
  • The trade is 1.4% of the 48,370,047 shares held after it.
  • 1 other insider bought within 30 days.
  • 68 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director DUGGAN ROBERT W bought about $13.0M of PLSE on May 11, 2026, the largest insider purchase at the company since 2023; 1 other insider bought within 30 days and 68 funds added in the latest 13F quarter.
68 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 63 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$13.8M over 180 days
+$199.9K over 90 days · +$13.0M of it by a 10%+ holder
more than 99% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
68 funds bought in last quarter
more than 52% of Medical Devices
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
16.0% of the float short (float per yahoo 2026-10-26) · 5.6 days to cover · settled 2026-09-30
more than 62% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch PLSE

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+202.7%12M
-27%+54%+136%+217%2025-102025-122026-022026-042026-062026-082026-10 2026-05-11 · DUGGAN ROBERT W bought $13.0M2026-02-11 · Danahy Kevin Patrick sold $504.0K2026-02-17 · Danahy Kevin Patrick sold $472.6K2026-02-13 · Danahy Kevin Patrick sold $470.6K2026-02-10 · Danahy Kevin Patrick sold $470.4K2026-02-12 · Danahy Kevin Patrick sold $467.4K2026-02-09 · Danahy Kevin Patrick sold $429.0K2026-05-11 · LAVIOLETTE PAUL A bought $295.4K2026-05-11 · LAVIOLETTE PAUL A bought $295.4K2026-02-18 · Danahy Kevin Patrick sold $118.2K2026-09-01 · Teplitsky Liane Rae bought $50.0K2026-08-28 · Teplitsky Liane Rae bought $50.0K2026-08-26 · Teplitsky Liane Rae bought $50.0K2026-08-31 · Teplitsky Liane Rae bought $50.0K
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns PLSE: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
1,466,702 sh
$40.7M
BANK OF AMERICA CORP /DE/
1,446,611 sh
$40.1M
VANGUARD CAPITAL MANAGEMENT LLC
788,640 sh
$21.9M
Portolan Capital Management, LLC
753,333 sh
$20.9M
Balyasny Asset Management L.P.
718,103 sh
$19.9M

Congress trades in PLSE

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

PLSE planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

PLSE mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
State Street(R) SPDR(R) S&P(R) Health Care Equipment ETF
$1.5M position · as of 2026-06-30
1.0%
Polen 5Perspectives Small Growth Fund
$304.6K position · as of 2026-07-31
0.5%
Zacks Small-Cap Core Fund
$148.2K position · as of 2026-05-31
0.4%
MFS New Discovery Series
$3.4M position · as of 2026-06-30
0.4%
MFS New Discovery Fund
$8.5M position · as of 2026-05-31
0.4%
Inspire Small/Mid Cap ETF
$634.0K position · as of 2026-05-31
0.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return · Mr Kevin Danahy
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$6.2M
n/a
$3.5M
-49%
n/a
2022
$424.3K
-$193.7K
$424.3K
-88%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
3 insiders reported buying shares.
The record shows a net $13.8M bought by insiders over 180 days, 68 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

PLSE financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.2M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-6,756%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$61.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-78.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-67.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
no debt line filed
Return on capital employed
-76.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Enterprise value
n/a
no debt line filed
FCF yield
-1.6%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$350.0K$0$0$700.0K
Operating income-$76.9M-$56.3M-$43.6M-$58.1M
Net income-$72.8M-$53.6M-$42.2M-$58.5M
Operating cash flow-$54.1M-$36.3M-$33.0M-$47.0M
Cash$80.7M$118.0M$44.4M$61.1M
SEC XBRL, fiscal years, as known on 2026-10-28

PLSE Stock Sonar score 4/7 axes

Find similar shapesCompare

PLSE ranks highest on insider conviction (91st percentile) and institutional and government (52nd), and lowest on profitability (26th), among Medical Devices peers.

Profitability
26
Inputs
  • Return on equity-78.5% · 30 pct, sector of 183
  • Return on assets-67.9% · 24 pct, sector of 214
  • Return on invested capitalno debt line filed
  • Return on capital employed-76.9% · 22 pct, sector of 188
Insider conviction
91
Inputs
  • Net Form 4 buying (codes P and S), 180d$13.8M · 99 pct, sector of 140
  • Insider buyers, 180d3 · 84 pct, sector of 142
Institutional and government
52
Inputs
  • Funds adding, latest quarter68 · 52 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
30
Inputs
  • Short interest, % of float+16.0% · 7 pct, sector of 240
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+9.9% · 52 pct, sector of 198
3 not measured: Financial health, Growth, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

PLSE filings, in plain words

Are Pulse Biosciences insiders buying or selling PLSE?

In the 180 days to 2026-10-28, Pulse Biosciences insiders were net buyers, a net $13.8M across purchases and sales reported on Form 4, by 3 buyers.

Read the full summary

In the 180 days to 2026-10-28, Pulse Biosciences insiders were net buyers of PLSE, a net $13.8M across purchases and sales reported on Form 4 by 3 buyers. Most of that figure, $13.0M, came from a holder of 10% or more rather than an officer or director. 3 insiders reported purchases in that window. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies